294 related articles for article (PubMed ID: 17693179)
1. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
[TBL] [Abstract][Full Text] [Related]
3. Is sapropterin treatment suitable for all subjects with phenylketonuria?
Doggrell SA
Expert Opin Pharmacother; 2008 Jan; 9(1):145-7. PubMed ID: 18076346
[TBL] [Abstract][Full Text] [Related]
4. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
Burton BK; Grange DK; Milanowski A; Vockley G; Feillet F; Crombez EA; Abadie V; Harding CO; Cederbaum S; Dobbelaere D; Smith A; Dorenbaum A
J Inherit Metab Dis; 2007 Oct; 30(5):700-7. PubMed ID: 17846916
[TBL] [Abstract][Full Text] [Related]
5. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
Sanford M; Keating GM
Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of sapropterin in patients with phenylketonuria.
Feillet F; Clarke L; Meli C; Lipson M; Morris AA; Harmatz P; Mould DR; Green B; Dorenbaum A; Giovannini M; Foehr E;
Clin Pharmacokinet; 2008; 47(12):817-25. PubMed ID: 19026037
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.
Lee P; Treacy EP; Crombez E; Wasserstein M; Waber L; Wolff J; Wendel U; Dorenbaum A; Bebchuk J; Christ-Schmidt H; Seashore M; Giovannini M; Burton BK; Morris AA;
Am J Med Genet A; 2008 Nov; 146A(22):2851-9. PubMed ID: 18932221
[TBL] [Abstract][Full Text] [Related]
8. Sapropterin. Phenylketonuria: for a minority of patients.
Prescrire Int; 2010 Jun; 19(107):101-4. PubMed ID: 20738029
[TBL] [Abstract][Full Text] [Related]
9. Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR; Merrin M
Cochrane Database Syst Rev; 2012 Dec; 12():CD008005. PubMed ID: 23235653
[TBL] [Abstract][Full Text] [Related]
10. Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR; Merrin M
Cochrane Database Syst Rev; 2010 Jun; (6):CD008005. PubMed ID: 20556789
[TBL] [Abstract][Full Text] [Related]
11. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).
Burton BK; Bausell H; Katz R; Laduca H; Sullivan C
Mol Genet Metab; 2010; 101(2-3):110-4. PubMed ID: 20638313
[TBL] [Abstract][Full Text] [Related]
12. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
[TBL] [Abstract][Full Text] [Related]
13. Sapropterin: a new therapeutic agent for phenylketonuria.
Hegge KA; Horning KK; Peitz GJ; Hegge K
Ann Pharmacother; 2009 Sep; 43(9):1466-73. PubMed ID: 19654333
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on sapropterin in primary hyperphenylalaninemia.
Sanford M; Keating GM
BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
[TBL] [Abstract][Full Text] [Related]
15. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.
Utz JR; Lorentz CP; Markowitz D; Rudser KD; Diethelm-Okita B; Erickson D; Whitley CB
Mol Genet Metab; 2012 Feb; 105(2):193-7. PubMed ID: 22112818
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.
Levy H; Burton B; Cederbaum S; Scriver C
Mol Genet Metab; 2007 Dec; 92(4):287-91. PubMed ID: 18036498
[TBL] [Abstract][Full Text] [Related]
17. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
[TBL] [Abstract][Full Text] [Related]
18. Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
Michals-Matalon K
Expert Opin Investig Drugs; 2008 Feb; 17(2):245-51. PubMed ID: 18230057
[TBL] [Abstract][Full Text] [Related]
19. Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency.
Cerone R; Andria G; Giovannini M; Leuzzi V; Riva E; Burlina A
Adv Ther; 2013 Mar; 30(3):212-28. PubMed ID: 23436109
[TBL] [Abstract][Full Text] [Related]
20. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered?
MacDonald A; Ahring K; Dokoupil K; Gokmen-Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Bélanger-Quintana A
Br J Nutr; 2011 Jul; 106(2):175-82. PubMed ID: 21466737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
